Claritas Pharmaceuticals, Inc. announced the addition of Professor Salvatore Cuzzocrea, Ph.D. as an independent member of the company’s board of directors effective immediately. Dr. Cuzzocrea is an acknowledged expert in the science and clinical use of nitric oxide therapy, and his appointment to the Board of Directors will position the company as a leader in the field of nitric oxide therapeutics. He currently serves in numerous leadership roles at the University of Messina in Sicily, including Director of Scientific Research, Director of the Department of Chemical, Biological, Pharmaceutical and Environmental Sciences, Director of the Oncology Unit at the University Hospital of Messina, and Full Professor of Pharmacology at the University’s School of Medicine.